



**COMPANY CONTACT:**

Endologix, Inc.  
Paul McCormick  
President and CEO  
(949) 595-7200  
[www.endologix.com](http://www.endologix.com)

**INVESTOR CONTACTS:**

Lippert/Heilshorn & Associates, Inc.  
Bruce Voss (bvoss@lhai.com)  
Jody Cain (jcain@lhai.com)  
(310) 691-7100  
[www.lhai.com](http://www.lhai.com)

**ENDOLOGIX TO PRESENT AT UBS 2007 GLOBAL LIFE SCIENCES  
CONFERENCE**

**IRVINE, Calif. (September 19, 2007)** – Endologix, Inc. (Nasdaq: ELGX), the developer and manufacturer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced that Paul McCormick, president and chief executive officer, will make a presentation to the investment community at the UBS 2007 Global Life Sciences Conference on Wednesday, September 26, 2007 at 4:00 p.m. Eastern time (1:00 p.m. Pacific time) at the Grand Hyatt Hotel in New York City.

Interested investors may gain access to a live audio webcast and accompanying slide presentation via the Internet by visiting the Company's Web site at [www.endologix.com](http://www.endologix.com). Please go to the Interviews/Presentations page on the Investor Relations section of the Web site. The presentation will be available and archived on the Web site for 30 days.

**About Endologix**

Endologix, Inc. develops and manufactures minimally invasive treatments for vascular diseases. Endologix's Powerlink System is an endoluminal stent graft (ELG) for treating abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it the thirteenth leading cause of death in the U.S. Additional information can be found on Endologix's Web site at [www.endologix.com](http://www.endologix.com).

# # #